Meet the team

The SymbiOx Team

Anil Sadarangani – PhD & MBA

Founder and VP of Business Development of SymbiOx

With experience in business development in the regenerative medicine biotechnology industry, Anil has lead and managed functional teams from preclinical and translational research and has a broad-based understanding of overall drug discovery and development from preclinical discoveries to market.

Tomás Egaña – PhD

Founder and VP of Technology of SymbiOx

Currently lab leader at Department of Plastic Surgery and Hand Surgery at Klinikum rechts der Isar, Technische Universität München. Tomás is also an engineer in molecular biotechnology, has a PhD in Human Biology from the University of Lübeck, Germany, as well as PhD in pharmacology from the University of Chile.

Andrés Völker – MBA

Founder and VP of Operations & Supply Chain of SymbiOx

With extensive experience in the development of new markets and new products, pricing products based on relevant information of each market and business line, development and implementation of marketing and advertising campaigns, and finance and administration.

Catalina Valencia, JD

VP, General Counsel of SymbiOx

With extensive experience working with start-ups in the strategic development of businesses and products, management of intellectual property portfolios and structuring and negotiation of complex transactions, Catalina was Senior Counsel for Genentech, the Biotech pioneer, during the early phase of research and development and expansion.

Saurabh Sharma – Student at UCSD

Software Engineer

Saurabh is currently a senior at UC San Diego studying Computer Science. He is passionate about applying technology to solve everyday problems. His past experience with other start-ups makes him a perfect fit for our team.


Advisors Core Expertise

Dennis Carson, MD
Moores Cancer Center Director

Dennis Carson joined the faculty at UC San Diego’s School of Medicine in 1990. From 2003 to 2011 he was the Director of the University’s Rebecca and John Moores Cancer Center, which builds relationships between scientific innovators and biotechnology companies. Dr. Carson has founded a number of drug-development companies, including Vical and Triangle Pharmaceuticals.

Jack DeFranco, MBA
President & CEO Targeson

President and Chief Executive Officer of Targeson Inc. He has experience in developing strategic partnerships, acquisitions, fund raising, and pharmaceutical operations management. He has held various management positions in business development, marketing and sales with Smith & Nephew Ltd. and Johnson and Johnson Inc. He has started 3 sales forces and created a U.S. wound care division for Smith and Nephew.

Kim Davis, MBA
Oversight committee for Evonexus

With over 17 years in the venture capital industry, Kim has been focused on investing and mentoring startups and high growth companies. Kim is also currently an Adjunct professor at SDSU, on the oversight committee for Evonexus a San Diego incubator and heads business development for Cashie Commerc and advice several early stage companies.

John Toomey
Regulatory expert

Medical devices industry consultant with twenty-six years of experience preparing numerous 510(k) premarket notifications and ISO registrations. Responsible for developing consistent regulatory affairs strategy approach, business development, intellectual property and involved in both FDA site audits and meetings with CDRH.

Noel C. Gillespie,
Chair of Procopio’s Medical Technology Practice Group

Noel C. Gillespie is the chair of Procopio’s Medical Technology Practice Group. Mr. Gillespie regularly assists clients with strategic patent portfolio development and implementation so as to protect their technology and help them achieve their business objectives. This process includes developing claim strategies that create market barriers and protect or create revenue streams, as well as preparing and prosecuting U.S. and foreign Patent Applications.

Mark Wilson, MBA
VP, Business Develop. Medincell

Chief Executive Officer. He has 25 years of executive management in the biotechnology field from Hybritech to Pfizer and Halozyme Therapeutics.

Yves Harder
Professor, Technische Universität München

Completed his training in General Surgery as well as in Plastic, Reconstructive and Aesthetic Surgery in Germany and Switzerland. Currently he works as a chief consultant in the Division of Plastic Surgery and Hand Surgery at the Technische Universität München in Munich, Germany, where is also Professor in Plastic Surgery.